ZA200403682B - N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation. - Google Patents

N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation.

Info

Publication number
ZA200403682B
ZA200403682B ZA200403682A ZA200403682A ZA200403682B ZA 200403682 B ZA200403682 B ZA 200403682B ZA 200403682 A ZA200403682 A ZA 200403682A ZA 200403682 A ZA200403682 A ZA 200403682A ZA 200403682 B ZA200403682 B ZA 200403682B
Authority
ZA
South Africa
Prior art keywords
adamantylmethyl
intermediates
derivatives
processes
preparation
Prior art date
Application number
ZA200403682A
Other languages
English (en)
Inventor
Lilian Alcaraz
Michael Stocks
Timothy Johnson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ZA200403682B publication Critical patent/ZA200403682B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA200403682A 2001-11-16 2004-05-13 N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation. ZA200403682B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0103836A SE0103836D0 (sv) 2001-11-16 2001-11-16 Novel compounds

Publications (1)

Publication Number Publication Date
ZA200403682B true ZA200403682B (en) 2005-08-03

Family

ID=20286020

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200403682A ZA200403682B (en) 2001-11-16 2004-05-13 N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation.

Country Status (29)

Country Link
US (1) US7129246B2 (https=)
EP (1) EP1448195B1 (https=)
JP (1) JP4559077B2 (https=)
KR (1) KR20040058290A (https=)
CN (1) CN1585640B (https=)
AR (1) AR037534A1 (https=)
AT (1) ATE344034T1 (https=)
AU (1) AU2002347741B2 (https=)
BR (1) BR0214142A (https=)
CA (1) CA2464863A1 (https=)
CO (1) CO5580747A2 (https=)
DE (1) DE60215851T2 (https=)
DK (1) DK1448195T3 (https=)
ES (1) ES2274110T3 (https=)
HU (1) HUP0402560A3 (https=)
IL (1) IL161693A0 (https=)
IS (1) IS7261A (https=)
MX (1) MXPA04004498A (https=)
MY (1) MY136430A (https=)
NO (1) NO20042155L (https=)
NZ (1) NZ532755A (https=)
PL (1) PL370855A1 (https=)
PT (1) PT1448195E (https=)
RU (1) RU2300525C2 (https=)
SE (1) SE0103836D0 (https=)
TW (1) TW200407297A (https=)
UA (1) UA77978C2 (https=)
WO (1) WO2003041707A1 (https=)
ZA (1) ZA200403682B (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258462B (en) 1999-12-17 2006-07-21 Astrazeneca Ab Adamantane derivative compounds, process for preparing the same and pharmaceutical composition comprising the same
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
SE0300480D0 (sv) * 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
MXPA05012705A (es) * 2003-05-29 2006-02-08 Astrazeneca Ab Una composicion farmaceutica que comprende un antagonista del receptor p2x7 y un factor alfa de necrosis tumoral.
US20070281931A1 (en) * 2003-05-29 2007-12-06 Nigel Boughton-Smith Pharmaceutical Composition Containing a P2x7 Receptor Antagonist and Methotrexate
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
KR100554155B1 (ko) * 2003-06-09 2006-02-22 학교법인 포항공과대학교 금속/반도체 나노막대 이종구조를 이용한 전극 구조물 및그 제조 방법
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
EP2591675A1 (en) 2006-11-27 2013-05-15 H. Lundbeck A/S Heteroaryl amide derivatives
CA2680761A1 (en) * 2007-03-22 2008-09-25 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases
WO2008124153A1 (en) 2007-04-10 2008-10-16 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
BRPI0910034B1 (pt) 2008-03-25 2022-02-08 Affectis Pharmaceuticals Ag Antagonistas do p2x7r e composições farmacêuticas que os compreendem
AU2010237302A1 (en) 2009-04-14 2011-12-01 Affectis Pharmaceuticals Ag Novel P2X7R antagonists and their use
SG185400A1 (en) 2010-05-14 2012-12-28 Affectis Pharmaceuticals Ag Novel methods for the preparation of p2x7r antagonists
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
CN103687860B (zh) 2011-07-22 2016-06-08 埃科特莱茵药品有限公司 作为p2x7受体拮抗剂的杂环酰胺衍生物
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
KR101576235B1 (ko) 2012-11-30 2015-12-11 한국생명공학연구원 신규한 이치환 아다만틸 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 암 전이 억제용 약학적 조성물
WO2014091415A1 (en) 2012-12-12 2014-06-19 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102232744B1 (ko) 2012-12-18 2021-03-26 이도르시아 파마슈티컬스 리미티드 Ｐ２ｘ７ 수용체 길항제로서의 인돌 카르복사미드 유도체
ES2616883T3 (es) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Derivados amida heterocíclicos como antagonistas del receptor P2X7
CA2896790C (en) 2013-01-22 2022-05-10 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
CN104163795B (zh) * 2014-08-19 2016-02-03 四川大学 盐酸烟酰美金刚胺溶剂合物、其制备方法和用途
CN104693084B (zh) * 2015-02-12 2016-03-16 佛山市赛维斯医药科技有限公司 含腈基苯基的n-金刚烷酰胺类化合物、其制备方法及用途
CN104628615B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 含卤代苯的n-金刚烷酰胺类化合物、其制备方法及其用途
CN104628616B (zh) * 2015-02-12 2016-06-01 佛山市赛维斯医药科技有限公司 含对硝基苯基的n-金刚烷酰胺类化合物、其制备方法及用途
CN104628617B (zh) * 2015-02-12 2016-04-06 佛山市赛维斯医药科技有限公司 N-金刚烷酰胺类葡萄糖激酶活化剂、制备方法及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) * 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) * 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
US4027035A (en) * 1968-08-27 1977-05-31 Eli Lilly And Company Therapeutic uses of adamantanealkylamine compounds
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) * 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
WO1990010622A1 (fr) * 1989-03-10 1990-09-20 Idemitsu Kosan Co. Ltd. Derives de pyridine et leurs sels, et agent insecticide/acaricide les contenant en tant qu'ingredient actif
CA2167154A1 (en) 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
US6034136A (en) * 1997-03-20 2000-03-07 Novartis Ag Certain cyclic thio substituted acylaminoacid amide derivatives
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
CZ20013608A3 (cs) 1999-04-09 2002-05-15 Astrazeneca Ab Adamantanové deriváty
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
ATE344034T1 (de) 2006-11-15
RU2004112780A (ru) 2005-10-10
PL370855A1 (en) 2005-05-30
HK1067048A1 (en) 2005-04-01
AR037534A1 (es) 2004-11-17
CA2464863A1 (en) 2003-05-22
IL161693A0 (en) 2004-09-27
HUP0402560A2 (hu) 2005-04-28
US7129246B2 (en) 2006-10-31
NO20042155L (no) 2004-08-16
PT1448195E (pt) 2007-02-28
CN1585640A (zh) 2005-02-23
MY136430A (en) 2008-10-31
CN1585640B (zh) 2010-10-27
MXPA04004498A (es) 2004-08-11
TW200407297A (en) 2004-05-16
WO2003041707A1 (en) 2003-05-22
CO5580747A2 (es) 2005-11-30
NZ532755A (en) 2005-11-25
JP2005519028A (ja) 2005-06-30
DE60215851T2 (de) 2007-05-24
US20050010052A1 (en) 2005-01-13
UA77978C2 (en) 2007-02-15
SE0103836D0 (sv) 2001-11-16
DK1448195T3 (da) 2007-02-12
HUP0402560A3 (en) 2009-03-02
JP4559077B2 (ja) 2010-10-06
EP1448195A1 (en) 2004-08-25
EP1448195B1 (en) 2006-11-02
IS7261A (is) 2004-05-13
DE60215851D1 (de) 2006-12-14
KR20040058290A (ko) 2004-07-03
RU2300525C2 (ru) 2007-06-10
BR0214142A (pt) 2004-09-14
AU2002347741B2 (en) 2008-03-13
ES2274110T3 (es) 2007-05-16

Similar Documents

Publication Publication Date Title
ZA200403682B (en) N-adamantylmethyl derivatives and intermediates as pharmaceutical composition and processes for their preparation.
HUP0401898A3 (en) 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates
HUP0401900A3 (en) 3-substituted-4-pyrimidone derivatives, pharmaceutical compositions containing them and their intermediates
IL162200A (en) 17a - ALKYL - 17?? - OXY - ESTRATRIENES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND INTERMEDIATES FOR THEIR PRODUCTION
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
AU2003246810A1 (en) Diphenylpyridine derivatives, the preparation thereof, and pharmaceutical compositions containing said derivatives
HUP0201278A3 (en) Pyrazolecarboamide derivative, its preparation, pharmaceutical compositions containing it and its intermediates
HUP0402338A3 (en) Spiro-hydantoin compounds, their use as anti-inflammatory agents, pharmaceutical compositions containing them and intermediates for preparing them
EP1450824A4 (en) PHARMACEUTICAL COMPOSITION
IL158898A0 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING APOMORPHINE, 6aR-(-)-N-PROPYL-NORAPOMORPHINE AND DERIVATIVES THEREOF
AU2002302147A1 (en) Pharmaceutical composition
GB0117057D0 (en) Pharmaceutical composition
AU2001292331A2 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
AU2001292331A1 (en) 5-amidino-2-hydroxybenzenesulfonamide derivatives, pharmaceutical compositions containing the same and intermediates for their preparation
HUP0401018A3 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
HUP0401082A3 (en) Substituted 4-aminocyclohexanols, process for their preparation and pharmaceutical compositions containing them
GB0116107D0 (en) Pharmaceutical composition
HUP0401829A3 (en) Substituted (1h)-quinoxalin-2-one compounds and substituted 4-aryl- or 4-heteroarylcyclohexane compounds, process for their preparation and pharmaceutical compositions containing the (1h)-quinoxalin-2-one compounds
SI1241169T1 (en) Isoindoloindolone derivatives, process for their preparation and pharmaceutical compositions containing them
SI1245565T1 (en) Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them
IL156861A0 (en) Pyrrole derivatives, pharmaceutical compositions containing the same and processes for the preparation thereof
HUP0402578A3 (en) 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino[4,5-b]indole-1-carboxamide derivatives, their preparation, their intermediates and pharmaceutical compositions containing the compounds
IL160606A0 (en) C2-substituted indan-1-ols and their derivatives, processes for their preparation and their use as pharmaceuticals
AUPR529701A0 (en) Pharmaceutical composition
IL160608A0 (en) C2-substituted indan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals